Tetsutaro Hamano

1.1k total citations
21 papers, 772 citations indexed

About

Tetsutaro Hamano is a scholar working on Oncology, Reproductive Medicine and Epidemiology. According to data from OpenAlex, Tetsutaro Hamano has authored 21 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Reproductive Medicine and 6 papers in Epidemiology. Recurrent topics in Tetsutaro Hamano's work include Ovarian cancer diagnosis and treatment (8 papers), Endometrial and Cervical Cancer Treatments (3 papers) and Adipokines, Inflammation, and Metabolic Diseases (3 papers). Tetsutaro Hamano is often cited by papers focused on Ovarian cancer diagnosis and treatment (8 papers), Endometrial and Cervical Cancer Treatments (3 papers) and Adipokines, Inflammation, and Metabolic Diseases (3 papers). Tetsutaro Hamano collaborates with scholars based in Japan, United States and Taiwan. Tetsutaro Hamano's co-authors include Tetsuya Hamaguchi, Yasuhiro Shimada, Ken Kato, Yasuhide Yamada, Koh Furuta, Takako Eguchi Nakajima, Takahisa Matsuda, Hitoshi Katai, Shin Fujita and Takuji Gotoda and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Tetsutaro Hamano

20 papers receiving 754 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tetsutaro Hamano Japan	12	293	280	212	204	136	21	772
Yoon Yang Jung South Korea	17	99 0.3×	160 0.6×	131 0.6×	199 1.0×	112 0.8×	44	641
Xiaoxin Ma China	19	74 0.3×	224 0.8×	425 2.0×	482 2.4×	80 0.6×	47	969
Kien Thiam Tan Taiwan	14	98 0.3×	233 0.8×	186 0.9×	273 1.3×	209 1.5×	40	707
Seung Ho Hong South Korea	17	80 0.3×	90 0.3×	102 0.5×	236 1.2×	242 1.8×	40	860
Ryoichi Asaka Japan	15	82 0.3×	88 0.3×	158 0.7×	297 1.5×	36 0.3×	38	634
Xiaoyan Ding China	13	87 0.3×	158 0.6×	148 0.7×	150 0.7×	68 0.5×	37	607
Megumi Kanasaki Japan	13	75 0.3×	190 0.7×	135 0.6×	345 1.7×	143 1.1×	27	890
Vasiliki Michalaki Greece	10	48 0.2×	355 1.3×	198 0.9×	170 0.8×	89 0.7×	37	707
Johannes Schmitt Germany	14	263 0.9×	149 0.5×	96 0.5×	131 0.6×	87 0.6×	28	542

Countries citing papers authored by Tetsutaro Hamano

Since Specialization

Citations

This map shows the geographic impact of Tetsutaro Hamano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsutaro Hamano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsutaro Hamano more than expected).

Fields of papers citing papers by Tetsutaro Hamano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tetsutaro Hamano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsutaro Hamano. The network helps show where Tetsutaro Hamano may publish in the future.

Co-authorship network of co-authors of Tetsutaro Hamano

This figure shows the co-authorship network connecting the top 25 collaborators of Tetsutaro Hamano. A scholar is included among the top collaborators of Tetsutaro Hamano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tetsutaro Hamano. Tetsutaro Hamano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kodama, Yoshihisa, Michihisa Moriguchi, Yoshitaka Inaba, et al.. (2025). Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. BMC Cancer. 25(1). 434–434. 3 indexed citations

Kawakami, Takeshi, Tetsutaro Hamano, Toshiki Masuishi, et al.. (2024). Prospective observational study investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival (OSERO study).. Journal of Clinical Oncology. 42(3_suppl). 103–103.

Yamazaki, Kentaro, Satoshi Yuki, Eiji Oki, et al.. (2021). Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. Clinical Colorectal Cancer. 20(3). e173–e184. 4 indexed citations

Yabuno, Akira, Hirokazu Matsushita, Tetsutaro Hamano, et al.. (2020). Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. Scientific Reports. 10(1). 18503–18503. 7 indexed citations

Sakai, Hitomi, Mikiko Asai‐Sato, Shinya Sato, et al.. (2020). A post-hoc study of relative dose intensity in elderly patients with advanced ovarian cancer (JGOG3016-A3).. Journal of Clinical Oncology. 38(15_suppl). e18053–e18053. 1 indexed citations

Kondo, Eiji, Tsutomu Tabata, Nao Suzuki, et al.. (2019). The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG).. Journal of Clinical Oncology. 37(15_suppl). 5515–5515. 1 indexed citations

Satoh, Toyomi, et al.. (2018). Effects of Anma therapy (Japanese massage) on health-related quality of life in gynecologic cancer survivors: A randomized controlled trial. PLoS ONE. 13(5). e0196638–e0196638. 15 indexed citations

Shoji, Tadahiro, Shinichi Komiyama, Junzo Kigawa, et al.. (2018). An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023. BMC Cancer. 18(1). 771–771. 17 indexed citations

Aotani, Eriko, Tetsutaro Hamano, Akihiko Gemma, et al.. (2016). Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer. International Journal of Clinical Oncology. 21(5). 836–842. 5 indexed citations

10.

Satoh, Toyomi, et al.. (2016). Physical effects of Anma therapy (Japanese massage) for gynecologic cancer survivors: A randomized controlled trial. Gynecologic Oncology. 142(3). 531–538. 6 indexed citations

11.

Ando, Masashi, Hideko Yamauchi, Kenjiro Aogi, et al.. (2014). Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Research and Treatment. 145(2). 401–409. 61 indexed citations

12.

Satoh, Toyomi, et al.. (2013). Effects of Anma massage therapy (Japanese massage) for gynecological cancer survivors: study protocol for a randomized controlled trial. Trials. 14(1). 233–233. 5 indexed citations

13.

Toita, Takafumi, Ryo Kitagawa, Tetsutaro Hamano, et al.. (2012). Feasibility and Acute Toxicity of Concurrent Chemoradiotherapy (CCRT) With High-Dose Rate Intracavitary Brachytherapy (HDR-ICBT) and 40-mg/m2 Weekly Cisplatin for Japanese Patients With Cervical Cancer. International Journal of Gynecological Cancer. 22(8). 1420–1426. 15 indexed citations

14.

Toita, Takafumi, Ryo Kitagawa, Tetsutaro Hamano, et al.. (2012). Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule. Gynecologic Oncology. 126(2). 211–216. 96 indexed citations

15.

Nakajima, Takako Eguchi, Yasuhide Yamada, Tetsutaro Hamano, et al.. (2010). Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Science. 101(5). 1286–1291. 190 indexed citations

16.

Fujiwara, K., Eriko Aotani, Tetsutaro Hamano, et al.. (2010). A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer. Japanese Journal of Clinical Oncology. 41(2). 278–282. 28 indexed citations

17.

Nakajima, Takako Eguchi, Yasuhide Yamada, Tetsutaro Hamano, et al.. (2009). Adipocytokines and squamous cell carcinoma of the esophagus. Journal of Cancer Research and Clinical Oncology. 136(2). 261–266. 41 indexed citations

18.

Nakajima, Takako Eguchi, Yasuhide Yamada, Tetsutaro Hamano, et al.. (2009). Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. Journal of Gastroenterology. 44(7). 685–690. 154 indexed citations

19.

Yamada, Yasuhide, Tokuzo Arao, Takuji Gotoda, et al.. (2008). Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Science. 99(11). 2193–2199. 79 indexed citations

20.

Kato, Yukinari, Norihito Hayatsu, Mika K. Kaneko, et al.. (2008). Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors. Biochemical and Biophysical Research Communications. 369(4). 1041–1046. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact